Acceptance of pharmaceutical cannabis substitution by cannabis using patients with schizophrenia

Acceptance of pharmaceutical cannabis substitution by cannabis using patients with schizophrenia

Abstract Background Cannabis-smoking patients with a psychotic disorder have poorer disease outcomes than non-cannabis-smoking patients with poorest outcomes in patients smoking high-potency cannabis (HPC) containing high Δ9-tetrahydrocannabinol (THC) and low cannabidiol (CBD). Quitting cannabis smo...

Full description

Bibliographic Details
Main Authors: Jan van Amsterdam, Jojanneke Vervloet, Gerdien de Weert, Victor J. A. Buwalda, Anna E. Goudriaan, Wim van den Brink
Format: Article
Language:English
Published: BMC 2018-09-01
Series:Harm Reduction Journal
Subjects:
Schizophrenia
Psychosis
Cannabis
Skunk
CBD
High-potency cannabis
Online Access:http://link.springer.com/article/10.1186/s12954-018-0253-7

Internet

http://link.springer.com/article/10.1186/s12954-018-0253-7

Similar Items